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The mean corpuscular volume (MCV) of peripheral blood mononuclear cells (PBMCs) was determined by
Coulter Counter, and data were used to calculate the intracellular drug concentrations. A total of 574 PBMC
samples were collected from 190 patients. The MCV was 282.9 fl (minimum, 207.0; maximum, 354.6), with a
standard deviation of 8.8%. Previous reports have often used a fixed value of 400 fl for the MCV, which may
result in artificially low estimates of the intracellular concentrations of antivirals.
A correlation between nonnucleoside reverse transcrip-
tase inhibitor (NNRTI) and protease inhibitor (PI) plasma
concentrations and efficacies has been described in several
studies, but it has to be considered that almost all antiret-
roviral agents act within HIV-infected cells. Consequently,
antiretroviral drug concentrations in peripheral blood
mononuclear cells (PBMCs) could represent a more reliable
measure of antiretroviral activity (2).
Several factors play a role in antiretroviral drug accumula-
tion in PBMCs. Antiretroviral physiochemical characteristics
affect intracellular diffusion of antiretrovirals, and lipophilic
compounds have higher concentrations (6). Influx and efflux
transporters are expressed on PBMC cellular membranes and
present a high intersubject variability of expression and activity
that influences intracellular concentrations (8).
Intracellular quantification of anti-HIV drugs requires sen-
sitive instrumentation due to the very low concentrations pres-
ent. Liquid chromatography coupled with mass spectrometry
(LC-MS or MS-MS) has been used for the determination of
drug concentrations in PBMCs, and numerous assays have
been published (3, 4, 8, 10, 12). Intracellular concentration is
generally expressed as the amount of drug per 106 cells; how-
ever, to evaluate the intracellular concentration/plasma con-
centration ratio, it is necessary to convert this to the amount of
drug per volume unit of cells. An arbitrary mean corpuscular
volume (MCV) of 400 fl for PBMCs is most frequently adopted
to convert the results (1, 9, 13). Consequently, quantification of
intracellular concentrations could be potentially biased by in-
terindividual variability of the MCV of PBMCs.
The aim of this study was to analyze the MCVs of PBMC
samples from a large group of patients infected with HIV by
use of a Coulter Counter. The MCV population data are re-
ported and discussed in relation to the adoption of the fixed
value of 400 fl for the PBMC volume.
Two EDTA tubes of blood samples (12 to 15 ml) were taken
from each HIV-positive patient receiving antiretroviral ther-
apy after their written informed consent was obtained in ac-
cordance with local ethic committee requirements.
PBMCs were isolated from 12 to 14 ml of blood by Lym-
phoprep density gradient centrifugation (700  g for 25 min at
4°C with a Jouan model BR4i centrifuge [Saint-Herblain,
France]) as previously described (9). PBMCs were then quickly
washed twice in 40 ml ice-cold phosphate-buffered saline
(PBS) to prevent drug loss (6) and centrifuged (700  g, 6 min,
4°C). During the last wash step, cell numbers and MCVs were
determined by diluting 500 l PBS cell suspension with 19.5 ml
of Isoton solution in a beaker (twice) and using a Beckman
Coulter Z2 (Instrumentation Laboratory, Milan, Italy) with the
following settings: aperture diameter, 100 m; 58.66 kDa; up-
per size limit, 12 m; lower size limit, 5.5 m. Eight counts for
each sample (four for each beaker) were performed, and the
final acquisition range was manually set for each sample to
exclude the eventual red blood cell contamination (Fig. 1).
Data were managed by Z2 AccuComp software (version 3.01).
The resulting pellet of washed PBMCs was dissolved with
1 ml extraction solution (methanol-water, 70:30 [vol/vol]),
switched in two cryovials (500 l each), and then stored at
80°C for subsequent high-pressure liquid chromatography
(HPLC)-MS analysis with a fully validated method (5). The
entire procedure took less than 1 h.
A total of 574 PBMC samples were collected from 190
patients, and clinical information for the patients is reported in
Table 1.
The mean MCV was 282.9 fl (minimum, 207.0; maximum,
354.6), with a standard deviation of 8.8%. The intrapatient
MCV standard deviation was 3.6% (4 to 8 samples per 37
patients were collected for the area under the concentration-
time curve [AUC] studies), and the interpatient MCV standard
deviation was 5.0% (3 to 8 samples per 47 patients). No sta-
tistically significant association between the mean values for
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sex, age, and body mass index (BMI) and the MCVs was
observed.
Concentration is, by definition, the amount of a substance in
a given volume. Therefore, intracellular drug concentration
corresponds to the ratio of the amount of drug inside the cell
to the cell volume. In practice, where blood samples contain
millions of PBMCs, the drug concentration in a certain number
of PBMCs (N PBMCs) is the sum of the drug amounts in cells
divided by the volume of the PBMCs. The last formula can be
expressed in a simpler way by using the MCV, as follows: [N
PBMCs]  (amount of drug in cells)/(MCV  N PBMCs).
Considering the final formula reported above, the evaluation
of intracellular drug concentrations can be biased by errors in
three different measurements: (i) the amount of the drug,
usually determined by HPLC-MS or MS-MS; (ii) the number
of PBMCs, usually counted using a Bürker/Malassez counting
chamber and microscope; and (iii) the MCV, presumptively
considered to be 400 fl. Therefore, to obtain accurate results,
it is necessary to carefully evaluate all three variables.
Although quantitative analysis data are obtained through
sophisticated and sensitive instruments, the PBMC counting
and MCV data result from the use of no special or precise
equipment.
The choice of 400 fl for the PBMC volume comes from the
work of Gao et al. (7) that is directly or indirectly cited in
several studies to justify data conversion. Gao et al. performed
their experiments with quiescent or activated peripheral blood
leukocytes (PBLs) stimulated with phytohemagglutinin (a mi-
togen agent) and, using a Coulter Counter, reported a volume
of 0.25 l per 106 cells for quiescent PBLs and 0.38 l per
106 cells for stimulated PBLs.
Because PBMCs are a heterogeneous population of cells
composed of lymphocytes and monocytes and are not activated
in a physiological situation (which increases their volume), a
value of 400 fl for the PBMC volume seems to be inappropri-
ate. Moreover, an exhaustive study on the cellular volume of
PBMCs (11) suggests mean volumes of 174 fl for lymphocytes
and 339 fl for monocytes, in accordance with our data (data not
shown).
Assessment of the data using our MCV versus 400 fl pro-
duced a mean percent error of 29.3% (Fig. 2).
In our study, the MCV observed using a Coulter Counter
was 282.9 fl, smaller than 400 fl. The use of 400 fl as a pre-
sumptive standard value of MCV and a manual cell count
could significantly bias the methods of quantification, and as a
result, previous reports may have potentially underestimated
intracellular drug exposure. Moreover, it has to be noted that
we detected an MVC ranging from 207.0 fl to 354.6 fl. Thus,
MCV quantification should be performed for each patient.
Therefore, we suggest calculation of individual MCVs and
automatic cell counting as more accurate and reliable tools to
quantify intracellular antiretroviral drug concentrations.
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FIG. 1. Representative graph of PBMC distribution in a patient
sample. Broken vertical lines mark the manually adopted range. Cir-
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TABLE 1. General clinical information of patients
Parameter Value
No. of patients ................................................................190
No. (%) of Caucasians ..................................................170 (90)
No. (%) of males............................................................124 (65)
Age (yr) mean (range)................................................ 44 (19–79)
Wt (kg) mean (range) ................................................. 69 (39–116)
BMI (kg/m2) mean (range) ........................................ 23.6 (15.7–35.8)
FIG. 2. The percent error in measuring intracellular drug concen-
trations is inversely correlated to the error in MCV evaluation. Use of
a 400-fl value for the MCV instead of our MCV produces a percent
error of 29.3% in drug concentration data.
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